Brinker Capital Investments’s Cytokinetics CYTK Stock Holding History

Brinker Capital Investments’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$589K	Sell	8,933 -2,700	-23%	-$172K	0.01%	1380
2025 Q4	$739K	Buy	11,633 +400	+4%	+$24.9K	0.01%	1399
2025 Q3	$617K	Buy	+11,233	New	+$463K	﹤0.01%	1459
2024 Q2	–	Sell	-3,168	Closed	-$222K	–	1727
2024 Q1	$222K	Buy	+3,168	New	+$245K	﹤0.01%	1577
2023 Q1	–	Sell	-4,847	Closed	-$222K	–	1576
2022 Q4	$222K	Sell	4,847 -34	-0.7%	-$1.46K	﹤0.01%	1264
2022 Q3	$236K	Sell	4,881 -2,595	-35%	-$125K	﹤0.01%	1214
2022 Q2	$294K	Buy	+7,476	New	+$301K	0.01%	1172
2022 Q1	–	Sell	-4,446	Closed	-$203K	–	1384
2021 Q4	$203K	Buy	+4,446	New	+$172K	﹤0.01%	1348

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Brinker Capital Investments's CYTK Position: Q1 2026 in Review

Brinker Capital Investments reduced its Cytokinetics (CYTK) stake by 23% in Q1 2026, selling an estimated $172K and leaving 8,933 shares worth $589K. The position accounts for 0.01% of the portfolio, ranked #1380.

Brinker Capital Investments first reported a position in CYTK in Q4 2021 and has held it in 8 quarters since. The position peaked at $739K in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Brinker Capital Investments held 8,933 shares of Cytokinetics worth $589K as of Q1 2026.
Brinker Capital Investments sold 2,700 Cytokinetics shares in Q1 2026, an estimated $172K.
Cytokinetics made up 0.01% of Brinker Capital Investments's portfolio in Q1 2026, its #1380 holding.
Brinker Capital Investments first reported a position in Cytokinetics in Q4 2021 and has held it in 8 quarters since.
Brinker Capital Investments's Cytokinetics position peaked at $739K in Q4 2025.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Brinker Capital Investments's 13F filing for Q1 2026, filed 13 May 2026.